Clovis' Perfect Story Gets Shredded
By Max Nisen
Nov 16, 2015
The response rate plunged from 67 percent to 28 percent for a smaller dose and 35 percent for a larger one. AstraZeneca's direct competitor Tagrisso, approved just last week, has a confirmed response rate about double that.
In other words, rocilitenib is, as Bloomberg Intelligence analyst Asthika Goonewardene puts it, "toast."
The Fly On the Wall
11/16/15 5:30 P.M. EST
Leerink Raises AstraZeneca Price Target to $75 after FDA requests added data for rociletinib
Says blocking plaque formation shows cognitive improvement
Love this story.. she was almost dying and now up and smiling,,, thanks for posting.
Adam Feuerstein @adamfeuerstein 52m52 minutes ago
Adam Feuerstein Retweeted hrbrendan
egg avatar, every tweet $AVXL. A classic example of the phony Twitter accounts used by promoters to tout the stock.
folks going to realize the scam this is and this stock going to go back up. VRX been in business over 10 years, with never a complaint.
10/26/15BioDelivery Sciences Opioid Gets FDA Approval for Chronic Pain